Get the Stockscreener App
65.62
1.16%
0.75
Cidara Therapeutics Inc stock is traded at $65.62, with a volume of 378.63K.
It is up +1.16% in the last 24 hours and up +5.84% over the past month.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$64.87
Open:
$64.43
24h Volume:
378.63K
Relative Volume:
0.49
Market Cap:
$1.66B
Revenue:
$302.00K
Net Income/Loss:
$-117.10M
P/E Ratio:
-5.8958
EPS:
-11.13
Net Cash Flow:
$-129.13M
1W Performance:
+3.88%
1M Performance:
+5.84%
6M Performance:
+185.30%
1Y Performance:
+478.15%
1-Day Range:
$63.50
$65.85
1-Week Range:
$61.10
$65.85
52-Week Range:
$10.14
$69.36
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Name
Cidara Therapeutics Inc
Sector
Industry
Phone
858-752-6170
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Compare CDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
65.62 | 1.61B | 302.00K | -117.10M | -129.13M | -11.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Mar-12-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-27-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Nov-08-24 | Initiated | Guggenheim | Buy |
| Aug-14-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-03-21 | Resumed | H.C. Wainwright | Buy |
| Sep-22-21 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-04-21 | Initiated | Aegis Capital | Buy |
| Sep-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Jul-26-18 | Initiated | Citigroup | Buy |
| Apr-21-17 | Initiated | Raymond James | Strong Buy |
| Apr-17-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-11-17 | Resumed | Wedbush | Outperform |
| Feb-22-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Upgrade | WBB Securities | Sell → Hold |
| Dec-21-16 | Resumed | Leerink Partners | Outperform |
| Dec-19-16 | Initiated | H.C. Wainwright | Buy |
| Sep-23-16 | Downgrade | WBB Securities | Hold → Sell |
| Oct-09-15 | Upgrade | WBB Securities | Sell → Hold |
| May-11-15 | Initiated | Jefferies | Buy |
| May-11-15 | Initiated | Leerink Partners | Outperform |
| May-11-15 | Initiated | Needham | Buy |
| May-11-15 | Initiated | Wedbush | Outperform |
| Apr-23-15 | Initiated | WBB Securities | Sell |
View All
Cidara Therapeutics Inc Stock (CDTX) Latest News
How buybacks impact Cidara Therapeutics Inc. stock valueMarket Growth Summary & Weekly Return Optimization Plans - baoquankhu1.vn
American Century Companies Inc. Buys Shares of 10,409 Cidara Therapeutics, Inc. $CDTX - MarketBeat
Adage Capital Partners GP L.L.C. Has $21.33 Million Holdings in Cidara Therapeutics, Inc. $CDTX - MarketBeat
Cidara Therapeutics, Inc. $CDTX Shares Sold by Checkpoint Capital L.P. - MarketBeat
How does Cidara Therapeutics Inc. compare to its peers2025 Trading Recap & Momentum Based Trading Ideas - Lancaster City Council
OMERS ADMINISTRATION Corp Boosts Stock Holdings in Cidara Therapeutics, Inc. $CDTX - MarketBeat
Bollinger Bands Show Potential Breakout in Cidara Therapeutics Inc.2025 Performance Recap & Accurate Intraday Trading Signals - beatles.ru
Cidara Therapeutics: Promising Trials Amidst Financial Challenges - MSN
Is Cidara Therapeutics Inc. still a buy after recent gainsJuly 2025 Selloffs & Daily Momentum Trading Reports - 뉴스영
Watch for Bullish Crossover in Cidara Therapeutics Inc.2025 Short Interest & Long-Term Safe Return Strategies - beatles.ru
Cidara Therapeutics, Inc. $CDTX Stake Reduced by BVF Inc. IL - MarketBeat
Vestal Point Capital LP Buys Shares of 504,542 Cidara Therapeutics, Inc. $CDTX - MarketBeat
Cidara Therapeutics, Inc. $CDTX Shares Sold by ADAR1 Capital Management LLC - MarketBeat
Relative strength of Cidara Therapeutics Inc. in sector analysisJuly 2025 Decliners & Expert Verified Stock Movement Alerts - Newser
Cidara Therapeutics Inc. stock daily chart insightsMarket Volume Report & Capital Efficient Trade Techniques - Newser
Pattern recognition hints at Cidara Therapeutics Inc. upsideBull Run & Daily Stock Momentum Reports - Newser
Is Cidara Therapeutics Inc. stock heavily shortedExit Point & Accurate Entry and Exit Point Alerts - خودرو بانک
Can Cidara Therapeutics Inc. expand its profit marginsQuarterly Portfolio Review & Smart Money Movement Alerts - خودرو بانک
Analyzing Cidara Therapeutics Inc. with multi timeframe chartsTrade Risk Report & Verified Technical Signals - Newser
Long term hold vs stop loss in Cidara Therapeutics Inc.Gold Moves & AI Forecast for Swing Trade Picks - Newser
Will Cidara Therapeutics Inc. price bounce be sustainable2025 Key Highlights & Technical Pattern Based Signals - Newser
Is Cidara Therapeutics Inc. a speculative investmentPortfolio Update Report & Risk Managed Trade Strategies - خودرو بانک
What Fibonacci levels say about Cidara Therapeutics Inc. reboundJuly 2025 Update & Weekly Stock Breakout Alerts - Newser
Will Cidara Therapeutics Inc. bounce back from current supportWeekly Profit Analysis & AI Forecasted Stock Moves - Newser
Comparing Cidara Therapeutics Inc. in custom built stock radarsWeekly Investment Report & Stock Portfolio Risk Management - Newser
Can technical indicators confirm Cidara Therapeutics Inc.’s reversal2025 Earnings Impact & Community Verified Swing Trade Signals - Newser
Can Cidara Therapeutics Inc. weather a recessionJuly 2025 Closing Moves & Fast Exit Strategy with Risk Control - خودرو بانک
Cidara Therapeutics to Participate in September Investor Conferences - 富途牛牛
Cidara Therapeutics to Present at Upcoming Investor Conferences in September 2025 - Quiver Quantitative
Is Cidara Therapeutics Inc. stock a value trapWeekly Risk Summary & Daily Profit Focused Stock Screening - خودرو بانک
Cidara Therapeutics Inc. stock momentum explainedStop Loss & Stepwise Trade Signal Implementation - Newser
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Crosses Above Fifty Day Moving AverageHere's What Happened - MarketBeat
Will Cidara Therapeutics Inc. stock recover after recent dropWeekly Loss Report & Community Driven Trade Alerts - Newser
What moving averages say about Cidara Therapeutics Inc.Jobs Report & Community Verified Watchlist Alerts - Newser
Does Cidara Therapeutics Inc. show high probability of reboundWeekly Trading Summary & Real-Time Volume Analysis - Newser
Why Cidara Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Patterns & Free Community Consensus Stock Picks - Newser
Cidara Therapeutics to Present Clinical Phase 2b Data and - GlobeNewswire
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting - MarketScreener
Breakthrough Flu Prevention Drug CD388 Data: Cidara Therapeutics Reveals Phase 2b Results at Major Conference - Stock Titan
Momentum divergence signals in Cidara Therapeutics Inc. chartTreasury Yields & AI Forecasted Stock Moves - Newser
Key resistance and support levels for Cidara Therapeutics Inc.Dip Buying & Fast Gain Stock Tips - Newser
Long term hold vs stop loss in Cidara Therapeutics IncQuarterly Growth Report & AI Powered Market Entry Ideas - Newser
Cidara Therapeutics Inc Stock (CDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):